- Jaguar Health, Inc. is implementing a 1-for-15 reverse stock split on September 17, 2026.
- This corporate action is intended to support Nasdaq listing standards compliance, particularly regarding minimum share price.
- The company’s subsidiary, Napo Pharmaceuticals, has advanced its clinical trial for Microvillus Inclusion Disease (MVID), with pediatric patients entering an extension phase.
Jaguar Health, Inc. (NASDAQ: JAGX) is a pharmaceutical company that develops plant-based medicines for people and animals. The company announced it will execute a 1-for-15 reverse stock split on September 17, 2026. This means that for every 15 shares an investor holds, they will be converted into a single share.
A reverse stock split is a corporate action that consolidates existing shares into fewer, higher-priced shares. As highlighted by Access Newswire, Jaguar Health is taking this step to support its compliance with Nasdaq’s listing standards, which often include a minimum share price. The split-adjusted shares will begin trading on September 17, 2026.
This decision comes as investors evaluate the company’s clinical development progress. As noted by Benzinga, Jaguar Health’s subsidiary, Napo Pharmaceuticals, announced that its trial for Microvillus Inclusion Disease (MVID) has advanced. All enrolled pediatric patients have now entered a single-blind extension phase to assess long-term safety and efficacy.
Following the news, the stock for Jaguar Health is trading lower at $0.21 per share. This reflects a daily decrease of 6.54%, or a drop of $0.02. Throughout the day, the stock’s price has ranged from a low of $0.21 to a high of $0.24, showing some volatility in its stock performance.
Over the past year, Jaguar Health has experienced a significant price range, reaching a high of $85.40 and a low of $0.20. The company currently has a market capitalization of approximately $13,988. The trading volume for the day is around 334,338 shares, indicating the level of investor interest and activity.
